The FDA has granted Medtronic 510(k) clearance for its Affinity Pixie oxygenation system.

MIAMI—A personally tailored hydration regimen can significantly reduce the incidence of kidney injury in patients at risk of contrast-induced nephropathy undergoing coronary angiography, researchers reported Oct. 25 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

MIAMI—Second-generation drug-eluting stents are feasible and effective in the treatment of unprotected left main coronary artery lesions, according to findings presented Oct. 24 at the late-breaking trials at the Transcatheter Cardiovascular Therapeutics conference.

MIAMI—Physicians should weigh the benefits and risks of more intensive antiplatelet therapy for patients in whom angiography is performed and coronary disease is confirmed, whether the patient receives medical therapy or PCI, according to the lead investigator of the late-breaking TRILOGY ACS trial presented Oct. 24 at the Transcatheter Cardiovascular Therapeutics (TCT) conference. However, because the overall TRILOGY trial was negative, the results of the trial are only hypothesis generating.

The 38 mm Resolute drug-eluting stent met its performance goal with a one-year target lesion failure (TLF) rate of 5.4 percent for patients being treated for long coronary artery lesions, according to findings presented Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics conference in Miami. The TLF rate among diabetic patients was similar.

MIAMI—Platelet reactivity monitoring is superior to a one-dose-fits-all strategy with prasugrel in reducing the rate of both high and low on-treatment platelet reactivity, which in turn impacts the adverse event rates in those patients, according to a study presented Oct. 22 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.

MIAMI—“You can’t use IVUS [intravascular ultrasound] to determine whether a lesion is less or equal to 0.8. For that determination, you need to use FFR [fractional flow reserve],” explained Gregg W. Stone, MD, as one of the take-home messages from the VERDICT F1RST/VERDICT PILOT trials, presented Oct. 22 at 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.

MIAMI—Dual-antiplatelet therapy (DAPT) cessation after stent implantation within one year was associated with an increased risk for all adverse events, an association that was strongest in the first seven days and attenuated after 30 days, according to the one-year results of the PARIS registry, presented Oct. 22 at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference.